BR112023022735A2 - Derivado de fosfonila e composição e aplicação farmacêutica do mesmo - Google Patents

Derivado de fosfonila e composição e aplicação farmacêutica do mesmo

Info

Publication number
BR112023022735A2
BR112023022735A2 BR112023022735A BR112023022735A BR112023022735A2 BR 112023022735 A2 BR112023022735 A2 BR 112023022735A2 BR 112023022735 A BR112023022735 A BR 112023022735A BR 112023022735 A BR112023022735 A BR 112023022735A BR 112023022735 A2 BR112023022735 A2 BR 112023022735A2
Authority
BR
Brazil
Prior art keywords
phosphonyl
derivative
composition
pharmaceutical application
pharmaceutical
Prior art date
Application number
BR112023022735A
Other languages
English (en)
Inventor
Anbang Huang
Chen Zhang
Chenfei Zhao
Fei Ye
Guofei Qian
Jia Ni
Jianmin Wang
Junjie Ma
Kai Li
Pangke Yan
Pingming Tang
Shaolong Zheng
Shuai Yuan
Yan Yu
Yao Li
Zhenggang Huang
Original Assignee
Xizang Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xizang Haisco Pharmaceutical Co Ltd filed Critical Xizang Haisco Pharmaceutical Co Ltd
Publication of BR112023022735A2 publication Critical patent/BR112023022735A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

derivado de fosfonila e composição e aplicação farmacêutica do mesmo. são fornecidos o composto mostrado na fórmula geral (i) ou um estereoisômero, um composto deuterado, um solvato, um pró-fármaco, um metabólito, um sal farmaceuticamente aceitável ou cocristal do mesmo, um intermediário do mesmo, e um uso do mesmo em doenças relacionadas ao egfr, como câncer. b-l-k (i).
BR112023022735A 2021-04-30 2022-04-29 Derivado de fosfonila e composição e aplicação farmacêutica do mesmo BR112023022735A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN202110470748 2021-04-30
CN202110570092 2021-05-25
CN202110651028 2021-06-11
CN202110824204 2021-07-22
CN202111025788 2021-09-03
CN202111214457 2021-10-22
CN202210000254 2022-01-06
PCT/CN2022/090243 WO2022228547A1 (zh) 2021-04-30 2022-04-29 一种膦酰衍生物及其组合物和药学上的应用

Publications (1)

Publication Number Publication Date
BR112023022735A2 true BR112023022735A2 (pt) 2024-01-02

Family

ID=83847797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022735A BR112023022735A2 (pt) 2021-04-30 2022-04-29 Derivado de fosfonila e composição e aplicação farmacêutica do mesmo

Country Status (10)

Country Link
EP (1) EP4332100A1 (pt)
JP (1) JP2024518363A (pt)
KR (1) KR20240005838A (pt)
CN (1) CN117425646A (pt)
AU (1) AU2022263747A1 (pt)
BR (1) BR112023022735A2 (pt)
CA (1) CA3217325A1 (pt)
IL (1) IL308103A (pt)
TW (1) TW202308655A (pt)
WO (1) WO2022228547A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023088385A1 (zh) * 2021-11-17 2023-05-25 浙江同源康医药股份有限公司 用于egfr蛋白降解的化合物及其用途
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2024032600A1 (zh) * 2022-08-08 2024-02-15 西藏海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3725771A4 (en) * 2017-12-13 2021-10-13 Shanghaitech University ALK PROTEIN DEGRADATION AGENT AND ITS ANTITUMOR APPLICATION
WO2019196812A1 (zh) * 2018-04-09 2019-10-17 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
CN111285849A (zh) * 2018-12-07 2020-06-16 上海青东生物科技有限公司 一种靶向降解ALK，c-Met和ROS1蛋白的化合物及其制备方法
CA3126976A1 (en) 2019-01-18 2020-07-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salt of egfr inhibitor, crystal form, and preparation method therefor
JP7426124B2 (ja) * 2019-06-12 2024-02-01 シャンハイテック ユニバーシティ Ａｌｋタンパク質レギュレーター、及びその抗腫瘍における使用
US20220306659A1 (en) * 2019-08-23 2022-09-29 Beijing Tide Pharmaceutical Co., Ltd. Compound inhibiting and inducing degradation of egfr and alk
EP4110340A1 (en) * 2020-02-25 2023-01-04 Dana-Farber Cancer Institute, Inc. Potent and selective degraders of alk
US20230248834A1 (en) * 2020-07-16 2023-08-10 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
US20230265116A1 (en) * 2020-07-16 2023-08-24 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use

Also Published As

Publication number Publication date
WO2022228547A1 (zh) 2022-11-03
CA3217325A1 (en) 2022-11-03
JP2024518363A (ja) 2024-05-01
KR20240005838A (ko) 2024-01-12
CN117425646A (zh) 2024-01-19
EP4332100A1 (en) 2024-03-06
IL308103A (en) 2023-12-01
AU2022263747A1 (en) 2023-12-14
TW202308655A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
BR112023022735A2 (pt) Derivado de fosfonila e composição e aplicação farmacêutica do mesmo
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
CY1118915T1 (el) Αντιβακτηριακα αναλογα αμινογλυκοσιδης
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
ECSP109934A (es) Compuesto - 946
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY31838A (es) Derivados de quinoxalin- y quinolin-carboxamida
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
EA201000886A1 (ru) Органические соединения
BR112021022897A2 (pt) Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo
CR11201A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
BR112014016635B8 (pt) composto, composição, e, uso de um composto
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto
BR112021011325A2 (pt) Derivados de rapamicina
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método